Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid (NCT06910670)
🩺 Plain-English Summary (8th-Grade Level)
The overall goal of the randomized control trial (RCT) will be to evaluate the efficacy of modifications to a web-based tool for patient decision-making regarding return of genomic results that will more closely focus on rare cancers. Participants will be given access to a web-based decision aid (or a standard control) that guides participants in making decisions about what type of genomic results they would like to receive from testing performed in the PE-CGS study (NCT06340646).
Who can join: Review the eligibility criteria below.
Location: Washington University School of Medicine — St Louis, Missouri
Age range: 18 Years
🧪 Interventions in This Study
- Standard developed materials (OTHER)
- Genetics Advisor Decision Aid (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Washington University School of Medicine — St Louis, Missouri
📞 Contact the Study Coordinator
Phone: (314) 747-1966
Email: elinnen@wustl.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cholangiocarcinoma
- Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations — Phoenix, Arizona
- An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma — Yerevan,
- Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma — Santa Monica, California
- [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma — Seattle, Washington
- Cell-Surface Plectin in the Diagnosis of Cholangiocarcinoma from ERCP-directed Biliary Samples — Charlottesville, Virginia
Explore by condition: All Cholangiocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.